IL26 and neoplasm: One is direct, involving the production of antibodies against tumor neoantigens and subsequent elimination of tumor cells; the other is indirect, based on the finding that CD4+ T lymphocytes activated by the HLA class II molecule – neoantigen complex induce proliferation of CD8+ T lymphocytes through the release of IL-26,7,9.